Roche Holding AG is considering options for its diabetes-care business including a sale, people familiar with the matter said, following other large drugmakers that have exited the treatment area amid price declines.
Alternatives being weighed also include a partial sale of the business or a spinoff, the people said, asking not to be identified because the deliberations are private. A sale could fetch as much as $5 billion, though the valuation could be affected by pricing pressure in the industry, they said. No final decisions have been made and Roche may decide to keep the unit, the people said. Chief Executive Officer Severin Schwan said Wednesday the company is committed to the business.